ΜΕΜΑ ΣΤΗ ΜΕΘ:
σε ποιους ασθενείς, πώς και ως πότε

ΙΩΑΝΝΑ ΣΙΓΑΛΑ
Πνευμονολόγος-Εντατικολόγος
Επιμελήτρια Ά ΕΣΥ
Ά Κλινική Εντατικής Θεραπείας ΕΚΠΑ,
Νοσοκομείο «Ευαγγελισμός»

NIV in ICU

- ❑ Weaning from MV
- ❑ Post extubation RF
- ❑ Hypoxemic RF-De novo
- ❑ Immunocompromised

NIV – weaning from MV

Persistent weaning failure



Sellares J et al Int Care Med (2011) 37:775–784

Hypercapnia at the end of a SBT predicts:
prolonged weaning & worse survival





Sellares J et al Int Care Med (2011) 37:775–784

Epidemiology of Weaning Outcome according to a New Definition The WIND Study

Beduneau G et al AJRCCM 2017; 195(6):772–783

- ❑ 36 ICUs
- ❑ 2,729 patients

Probability of death %



Days after the 1st Separation Attempt

Physiological Response to Pressure Support Ventilation Delivered before and after Extubation in Patients Not Capable of Totally Spontaneous Autonomous Breathing

MICHELE VITACCA, NICOLINO AMBROSINO, ENRICO CLINI, ROBERTO PORTA, CIRO RAMPULLA, BARBARA LANINI, and STEFANO NAVA

Am J Respir Crit Care Med Vol 164. pp 638–641, 2001



NIV ως μέθοδος weaning

ασθενείς με ΧΑΠ που απέτυχαν στο SBT μετά από 2 ημέρες MV



Nava et al. Ann Intern Med 1998;128:721

Θνητότητα στις 60 μέρες (%) - ασθενείς με οξεία παρόξυνση ΧΑΠ που έλαβαν NIV σαν weaning technique



Nava et al. Ann Intern Med 1998;128:721

NIV during persistent (3 days) spontaneous breathing trial failure

Successfully Weaned patients



SURVIVAL



COPD: 77 % (25 / 43) patients

Ferrer et al. AJRCCM 2003;168:70-76

NIV during persistent (3 days) spontaneous breathing trial failure

	NIV Group (*n* = 21)	Conventional-Weaning Group (*n* = 22)	p Value
Duration of invasive ventilation, d	9.5 ± 8.3	20.1 ± 13.1	0.003
Total period of ventilatory support*, d	11.4 ± 8.0	20.1 ± 13.1	0.012
ICU stay, d	14.1 ± 9.2	25.0 ± 12.5	0.002
Hospital stay, d	27.8 ± 14.6	40.8 ± 21.4	0.026
Reintubation, n (%)	3 (14)	6 (27)	0.457
Tracheotomy, n (%)	1 (5)	13 (59)	<0.001
ICU survival, n (%)	19 (90)	13 (59)	0.045

Ferrer et al. AJRCCM 2003;168:70-76

Effect of noninvasive weaning on MORTALITY

COPD population

Subgroup and study	Noninvasive No. of events	Noninvasive No. of patients	Invasive No. of events	Invasive No. of patients	RR (95% CI)
COPD					
Chen et al. 2001[31]	0	12	3	12	0.14 (0.01 to 2.50)
Nava et al. 1998[36]	2	25	7	25	0.29 (0.07 to 1.24)
Prasad et al. 2009[35]	5	15	9	15	0.56 (0.24 to 1.27)
Rabie Agmy et al. 2004[30]	1	19	2	18	0.47 (0.05 to 4.78)
Rabie Agmy et al. 2012[26]	7	134	26	130	0.26 (0.12 to 0.58)
Wang et al. 2004[32]	1	14	2	14	0.50 (0.05 to 4.90)
CRGNMV 2005[37]	1	47	7	43	0.13 (0.02 to 1.02)
Zheng et al. 2005[33]	3	17	3	16	0.94 (0.22 to 4.00)
Zou et al. 2006[34]	3	38	11	38	0.27 (0.08 to 0.90)
Subtotal		321		311	0.36 (0.24 to 0.56)
Total events	23		70		
$I^2 = 0\%$					



Burns KE et al CMAJ 2014;186(3):E112-22

Effect of noninvasive weaning on MORTALITY

Mixed population

Subgroup and study	Noninvasive No. of events	Noninvasive No. of patients	Invasive No. of events	Invasive No. of patients	RR (95% CI)
Mixed					
Ferrer et al. 2003[39]	6	21	13	22	0.48 (0.23 to 1.03)
Girault et al. 1999[38]	0	17	2	16	0.19 (0.01 to 3.66)
Girault et al. 2011[25]	16	69	9	69	1.78 (0.84 to 3.75)
Hill et al. 2000[29]	1	12	1	9	0.75 (0.05 to 10.44)
Tawfeek et al. 2012[27]	2	21	6	21	0.33 (0.08 to 1.47)
Trevisan et al. 2008[40]	9	28	10	37	1.19 (0.56 to 2.53)
Vaschetto et al. 2012[28]	2	10	3	10	0.67 (0.14 to 3.17)
Subtotal		178		184	0.81 (0.47 to 1.40)
Total events	36		44		
I^2 = 35%					
Total		499		495	0.53 (0.36 to 0.80)
Total events	59		114		
I^2 = 37%					
Test for subgroup differences p = 0.02, I^2 = 80.5%					



Burns KE et al CMAJ 2014;186(3):E112-22

Effect of noninvasive weaning on VAP

COPD

Mixed

Subgroup and study	Noninvasive No. of events	Noninvasive No. of patients	Invasive No. of events	Invasive No. of patients	RR (95% CI)
COPD					
Chen et al. 2001[31]	0	12	7	12	0.07 (0.00 to 1.05)
Nava et al. 1998[36]	0	25	7	25	0.07 (0.00 to 1.11)
Prasad et al. 2009[35]	1	15	5	15	0.20 (0.03 to 1.51)
Rabie Agmy et al. 2004[30]	0	19	4	18	0.11 (0.01 to 1.83)
Rabie Agmy et al. 2012[26]	3	134	30	130	0.10 (0.03 to 0.31)
Wang et al. 2004[32]	1	14	8	14	0.13 (0.02 to 0.87)
CRGNMV 2005[37]	3	47	12	43	0.23 (0.07 to 0.76)
Zheng et al. 2005[33]	1	17	4	16	0.24 (0.03 to 1.89)
Zou et al. 2006[34]	7	38	15	38	0.47 (0.21 to 1.01)
Subtotal		321		311	0.22 (0.13 to 0.37)
Total events	16		92		
$I^2 = 3\%$					
Mixed					
Ferrer et al. 2003[39]	5	21	13	22	0.40 (0.17 to 0.93)
Girault et al. 1999[38]	1	17	1	16	0.94 (0.06 to 13.82)
Girault et al. 2011[25]	9	69	10	69	0.90 (0.39 to 2.08)
Tawfeek et al. 2012[27]	1	21	8	21	0.13 (0.02 to 0.91)
Trevisan et al. 2008[40]	1	28	17	37	0.08 (0.01 to 0.55)
Subtotal		156		165	0.38 (0.15 to 0.93)
Total events	17		49		
$I^2 = 52\%$					
Total		477		476	0.25 (0.15 to 0.43)
Total events	33		141		
$I^2 = 38\%$					
Test for subgroup differences $p = 0.31$, $I^2 = 1.2\%$					



Burns KE et al CMAJ 2014;186(3):E112-22

Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure

Eur Respir J 2017; 50 (2): 1602426

Should NIV be used to facilitate weaning patients from invasive mechanical ventilation?

Recommendations

We suggest NIV be used to facilitate weaning from mechanical ventilation in patients with hypercapnic respiratory failure.
(Conditional recommendation, moderate certainty of evidence.)

We do not make any recommendation for hypoxaemic patients.

1

- Acute exacerbation of COPD
- Hypercapnia – respiratory acidosis
- tubation for respiratory acidosis

MV
hypercapnia & respiratory acidosis

2



, Obesity
onia on x-ray
Hypoxemia – respiratory acidosis
Intubation

- 2-days under MV
- FiO2: 60%, temperature:38oC
- SBT: failed with hypercapnia & respiratory acidosis

NIV be used to facilitate weaning

- **WHO:**
  - Patients with **COPD - hypercapnic respiratory failure & failed SBT**

- **HOW:**
  - **immediately after extubation**
  - **face mask**
  - **Pressure support mode** (BiPAP or BiPAP ST)
    - satisfactory ABGs and a RR< 25 breaths/min, SpO2>92%

  - In case of weaning (T-Piece) trial failure:
    - Reconnect patient to the ventilator in PS mode until the previous PaC02 and pH values are reached and the RR ≤ 30 breaths/min - (30 to 60 minutes)

- **HOW LONG**
  - As much **as possible during the first 24-48** - until it is well tolerated (**ideally >20 hours**)
  - Then, **gradually withdraw** - if patients can tolerate spontaneous breathing – until they could permanently sustain spontaneous breathing

NIV –postextubation RF

NIV και αναπνευστική ανεπάρκεια μετά την αποσωλήνωση

- **Επαναδιασωλήνωση** μετά από επιτυχημένη δοκιμασία αποδέσμευσης από τον αναπνευστήρα
  - 23% σε μεικτούς πληθυσμούς
  - 40-50% σε πληθυσμούς υψηλού κινδύνου πχ υπερκαπνικοί ασθενείς με ΧΑΠ
- **Αναπνευστική ανεπάρκεια** που εμφανίζεται 24-72 ώρες από την αποδέσμευση από τον αναπνευστήρα
- Συνοδεύεται από **αυξημένη θνητότητα**
  - 30-50% σε διάφορες μελέτες
- Η επαναδιασωλήνωση αποτελεί ανεξάρτητο παράγοντα κινδύνου για ανάπτυξη **νοσοκομειακής πνευμονίας**, αυξάνοντας την διάρκεια νοσηλείας σε ΜΕΘ και νοσοκομείο καθώς και την θνητότητα

Noninvasive Positive-Pressure Ventilation for Respiratory Failure after Extubation

Andrés Esteban, M.D., Ph.D., Fernando Frutos-Vivar, M.D., Niall D. Ferguson, M.D., Yaseen Arabi, M.D., Carlos Apezteguía, M.D., Marco González, M.D., Scott K. Epstein, M.D., Nicholas S. Hill, M.D., Stefano Nava, M.D., Marco-Antonio Soares, M.D., Gabriel D'Empaire, M.D., Inmaculada Alía, M.D., and Antonio Anzueto, M.D.

The New England Journal of Medicine

NEJM 2004;350:2452-60.



Noninvasive Positive-Pressure Ventilation for Respiratory Failure after Extubation

Andrés Esteban, M.D., Ph.D., Fernando Frutos-Vivar, M.D.,
Niall D. Ferguson, M.D., Yaseen Arabi, M.D.,
Carlos Apezteguía, M.D., Marco González, M.D., Scott K. Epstein, M.D.,
Nicholas S. Hill, M.D., Stefano Nava, M.D., Marco-Antonio Soares, M.D.,
Gabriel D'Empaire, M.D., Inmaculada Alía, M.D., and Antonio Anzueto, M.D.

The New England Journal of Medicine

NEJM 2004;350:2452-60.

	Mortality	Re-intubation
Non Invasive Ventilation N=114	25%	49%
Conventional Treatment N=107	14%	49%
P value	0.05	ns

Noninvasive Positive-Pressure Ventilation for Respiratory Failure after Extubation

Andrés Esteban, M.D., Ph.D., Fernando Frutos-Vivar, M.D., Niall D. Ferguson, M.D., M.Sc., Yaseen Arabi, M.D., Carlos Apezteguía, M.D., Marco González, M.D., Scott K. Epstein, M.D., Nicholas S.Hill, M.D., Stefano Nava, M.D., Marco-Antonio Soares, M.D., Gabriel D'Empaire, M.D., Inmaculada Alía, M.D., and Antonio Anzueto, M.D.*

N Engl J Med 2004;350:2452-60.

[redacted] In addition, noninvasive positive-pressure ventilation does not improve survival and may in fact be harmful. Although selected patients in specialized centers may benefit from this therapy, specific hypotheses need to be tested prospectively.

TIME to REINTUBATION
effect on MORTALITY



Epstein and Ciubotaru AJRCCM 1998;158:489-93

Ένας άλλος τρόπος θεώρησης του προβλήματος

Αν το κρίσιμο σημείο είναι ο χρόνος γιατί να περιμένουμε μέχρι την εμφάνιση της αναπνευστικής ανεπάρκειας (μετά την αποσωλήνωση) ?

Early Noninvasive Ventilation Averts Extubation Failure in Patients at Risk

A Randomized Trial

Miquel Ferrer, Mauricio Valencia, Josep Maria Nicolas, Oscar Bernadich, Joan Ramon Badia, and Antoni Torres

Am J Respir Crit Care Med Vol 173. pp 164–170, 2006

- Εφαρμογή NIV ή όχι **άμεσα** μετά την επιτυχή αποσωλήνωση
- Σε **άτομα αυξημένου κινδύνου** για εμφάνιση αναπνευστικής ανεπάρκειας
  - Ηλικία >65
  - Καρδιακή ανεπάρκεια
  - APACHE-II>12 (την ημέρα της αποσωλήνωσης

- **169 ασθενείς**
  - **79 NIV για 24 ώρες**
  - **83 οξυγονοθεραπεία**
- **Χρήση NIV σαν rescue therapy**: και στις 2 ομάδες

NIV για την αποφυγή αποτυχίας αποσωλήνωσης
σε ασθενείς με επιτυχημένο SBT

Αναπνευστική ανεπάρκεια

33 %

16 %



Μείωση μεγαλύτερη στο 1ο 24ωρο

Ferrer et al. AJRCM 2006;173:164-70

Survival –NIV to prevent postextubation RF







Ferrer et al. AJRCCM 2006;173:164-70

Non-invasive ventilation after extubation in hypercapnic patients with chronic respiratory disorders: randomised controlled trial

Miquel Ferrer, Jacobo Sellarés, Mauricio Valencia, Andres Carrillo, Gumersindo Gonzalez, Joan Ramon Badia, Josep Maria Nicolas, Antoni Torres

Lancet 2009; 374: 1082–88

- Εφαρμογή NIV ή όχι **άμεσα** μετά την επιτυχή αποσωλήνωση
- **Σε άτομα**
  - με **χρόνια αναπνευστική νόσο**
  - **Υπερκαπνία στο SBT** ($PaCO_2$>45mmHg)

- **106 ασθενείς**
  - 54 NIV για 24 ώρες
  - 52 οξυγονοθεραπεία
- Χρήση : **NIV σαν rescue therapy** και στις 2 ομάδες



Ferrer et al, Lancet 2009;374:1082-88

NIV μετά την αποσωλήνωση σε ασθενείς που ανέπτυξαν υπερκαπνία στο SBT



Number at risk										
Control	52	47	45	41	40	40	38	38	37	36
Non-invasive ventilation	54	51	50	49	48	48	48	48	48	48

Ferrer et al, Lancet 2009;374:1082-88

Easily identified at-risk patients for extubation failure may benefit from noninvasive ventilation: a prospective before-after study

AW Thille, F Boissier, H Ben-Ghezala, K Razazi, A Mekontso-Dessap, C Brun-Buisson & L Brochard

Critical Care (2016) 20:48 38:177-181



Re-intubation Rate



Thille AW et al Crit Care (2016) 20:48 38:177-181

Noninvasive ventilation for avoidance of reintubation in patients with various cough strength

Jun Duan*, Xiaoli Han, Shicong Huang and Linfu Bai

Critical Care (2016) 20:316





Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure

Eur Respir J 2017; 50 (2): 1602426

Should NIV be used to <u>prevent</u> respiratory failure post-extubation?

Recommendations

- ❑ We suggest that NIV **be used** to **<u>prevent</u>** post-extubation respiratory failure in **high-risk patients** post-extubation.
  (Conditional recommendation, low certainty of evidence.)

- ❑ We suggest that NIV should **not be used** to **<u>prevent</u>** post-extubation respiratory failure in **non-high-risk patients**.
  (Conditional recommendation, very low certainty of evidence.)

Liberation From Mechanical Ventilation in Critically Ill Adults: An Official American College of Chest Physicians/American Thoracic Society Clinical Practice Guideline

Inspiratory Pressure Augmentation During Spontaneous Breathing Trials, Protocols Minimizing Sedation, and Noninvasive Ventilation Immediately After Extubation

CHEST 2017; 151(1):166-180

AJRCCM 2017;195(1):115–119

3. For patients at high risk for extubation failure who have been receiving mechanical ventilation for more than 24 h, and who have passed an SBT, we recommend extubation to preventative NIV (Strong Recommendation, Moderate Quality of Evidence).

Patients at high risk for failure of extubation

- ❑ patients with hypercapnia
- ❑ COPD
- ❑ congestive heart failure
- ❑ other serious comorbidities.

Physicians who choose to use **NIV** should apply such treatment **immediately after extubation** to realize the outcome benefits

Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure

Eur Respir J 2017; 50 (2): 1602426

Should NIV be used in the <u>treatment</u> of respiratory failure that develops post-extubation?

Recommendation

- ❑ We suggest that NIV should **<u>not be used</u> in the <u>treatment</u> of patients with established post-extubation respiratory failure**.
  (Conditional recommendation, low certainty of evidence.)

- ➢ **This recommendation may <u>not apply to post-extubation COPD patients with respiratory failure</u>.** Further studies are needed

1

- Acute exacerbation of COPD
- Hypercapnia – respiratory acidosis
- Failed NIV – intubation for respiratory acidosis

capnia mild respiratory acidosis

2



y
x-ray
mia – respiratory acidosis

- 3-days under MV
- FiO2: 40%, no fever
- SBT: Success – hypercapnia mild respiratory acidosis

- **WHO:**
  - Patients **high-risk patients** **for post-extubation RF - TO PREVENT**
    - hypercapnic RF
    - COPD
    - Morbidly obese
    - congestive heart failure -CHF
    - Weak cough
    - Comorbidities other than CHF

- **HOW:**
  - immediately after extubation
  - face mask
  - Pressure support mode (BiPAP or BiPAP ST)
    - satisfactory ABGs and a RR< 25 breaths/min, SpO2>92%

- **HOW LONG**
  - 24-48 hours post-extubation
  - Immediately post-extubation: continuously as much as possible
  - Afterwards: alternating 4-hour Periods NIV /periods of Oxygen / High flow Nasal cannula Oxygen
  - ≥ 6hours /day

NIV in acute Hypoxemic RF
de novo RF

Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure

Eur Respir J 2017; 50 (2): 1602426

Should NIV be used in *de novo* ARF?

Recommendation

- **Given the uncertainty of evidence we are unable to offer a recommendation on the use of NIV for *de novo* ARF**

Endotracheal intubation rate

Study or Subgroup	NIPPV Events	NIPPV Total	Standard Oxygen Therapy Events	Standard Oxygen Therapy Total	Weight	Risk Ratio M-H, Fixed, 95% CI
Antonelli et al. 2000[20]	3	8	6	7	10.6%	0.44 (0.17–1.12)
Auriant et al. 2001[22]	5	24	12	24	19.9%	0.42 (0.17–1.00)
Delclaux et al. 2000[21]	15	40	18	41	29.5%	0.85 (0.50–1.45)
Ferrer et al. 2003[23]	6	7	8	8	13.3%	0.86 (0.60–1.24)
Zhan et al. 2012[24]	1	21	4	19	7.0%	0.23 (0.03–1.85)
Zhi et al. 2012[25]						9 (0.19–0.84)
Total (95% CI)						(0.44–0.80)
Total events	35		59			

Heterogeneity: $\chi^2 = 8.82$, df = 5 ($P = 0.12$); $I^2 = 43\%$

Test for overall effect: $z = 3.44$ ($P = 0.0006$)

Average NIV failure rate ≈50%



ICU mortality rate

Study or Subgroup	NIPPV Events	NIPPV Total	Standard Oxygen Therapy Events	Standard Oxygen Therapy Total	Weight	Risk Ratio M-H, Fixed, 95% CI
Antonelli et al. 2000[20]	3	8	4	7	14.1%	0.66 (0.22–1.97)
Delclaux et al. 2000[21]	9	40	9	41	29.3%	1.02 (0.45–2.32)
Ferrer et al. 2003[23]	5	7	7	8	21.6%	0.82 (0.48–1.40)
Zhan et al. 2012[24]	1	21	5	19	17.3%	0.18 (0.02–1.41)
Zhi et al. 2012[25]	3	15	5	13	17.7%	0.52 (0.15–1.77)
Total (95% CI)		**91**		**88**	**100.0%**	**0.69 (0.45–1.07)**
Total events	21		30			

Heterogeneity: $\chi^2 = 3.11$, df = 4 ($P = 0.54$); $I^2 = 0\%$

Test for overall effect: $z = 1.65$ ($P = 0.10$)



Luo J et al. Respirology (2014) 19, 1149–1157

it seems quite attractive to avoid ETI in 50% of patients with ARDS who undergo a NIV trial

The question to be asked might then probably be:

Can we correctly identify the 50% of patients with ARDS who would succeed in a NIV trial without harm and possibly avoid the complications related to ETI?

LUNG SAFE Study

Bellani G et al. AJRCCM 2017;195(1):67–77

- 459 ICUs & 50 countries
- 2813 patients with ARDS
- **NIV as initial management: 15.5%**
  - days 1 and 2 - at least 24 hours
  - **irrespective of the severity of hypoxemia**

- **NIV Success: 65%**
- **NIV Failure: 35%** switched to IMV
  - **Mild ARDS:** 22.2%,
  - **Moderate ARDS**: 42.3%
  - **Severe ARDS:** 47.1%

Hospital mortality

- **NIV as initial treatment**
  - **NIV success: 16.1%**
  - **NIV failure: 45.4%**
- **IMV as initial treatment**
  - **Mild ARDS: 34.9%**
  - **Moderate ARDS: 40.3%**
  - **Severe ARDS: 46.1%**

Factors associated with NIV failure

- Higher non pulmonary SOFA score
- Lower PaO2/FIO2
- the % ↑PaCO2 the first 2 days

LUNG SAFE Study

Kaplan-Meier survival curves

PaO2/FIO2 <150 mmHg



PaO2/FIO2 ≥150 mmHg



Bellani G et al. AJRCCM 2017;195(1):67–77



Overall rate of intubation of 54%

Non-ARDS causes

- pneumonia
- Atelectasis
- aspiration
- intra-alveolar hemorrhage
- pleural effusion
- extra-pulmonary sepsis

moderate ARDS – intubation rate

- ❑ **PaO2/FiO2<150: 74%**
- ❑ **PaO2/FiO2>150: 45%**

Thille et al. Critical Care 2013, 17:R269

Rate of in-ICU mortality in patients with moderate or severe ARDS



Intubation after NIV failure N=45

Intubation without prior NIV N=71

median delay between NIV initiation and intubation



Survivors N=33

Non-Survivors N=28

patients intubated within the first 96 h

Thille et al. Critical Care 2013, 17:R269

The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812 JUNE 4, 2015 VOL. 372 NO. 23

High-Flow Oxygen through Nasal Cannula in Acute Hypoxemic Respiratory Failure

- randomized, multicenter trial
- **23 ICU France & Belgium**
- **310 patients** with acute hypoxemic RF PaO2:FiO2≤300 mm Hg

- 1/1/1
  - high-flow oxygen
  - NIV
  - standard oxygen therapy

- **patients with severe initial hypoxemia** (Pao2:Fio2 ≤200 : **77%**

- **Bilateral Pulmonary infiltrates** - **79%**

Frat JP et al. NEJM 2015;372:2185-96

Incidence of Intubation

PaO2:FiO2 ≤ 200mmHg



Probability of Survival from Randomization to Day 90



hazard ratio for death at 90 days compared with High Flow oxygen

- ❑ **Standard oxygen 2.01**
- ❑ **NIV:2.5**

EJM 2015;372:2185-96

intubation rates

PaO2/FiO2 (150mmHg)

PaO2/FiO2 (200mmHg)

	HFNC Events	HFNC Total	NIPPV Events	NIPPV Total	Weight	Odds Ratio M-H, Fixed, 95% CI
Coudroy 2016	21	60	30	55	12.3%	0.45 [0.21, 0.95]
Frat 2015	40	106	55	110	20.2%	0.61 [0.35, 1.04]
Nagata 2015	0	33	10	43	5.4%	0.05 [0.00, 0.85]
Subtotal (95% CI)		**199**		**208**	**37.9%**	**0.48 [0.31, 0.73]**
Total events	61		95			
Heterogeneity: Chi² = 3.25, df = 2 (P = 0.20); I² = 38%						
Test for overall effect: Z = 3.44 (P = 0.0006)						
Hernández 2016	66	290	60	314	26.8%	1.25 [0.84, 1.85]
Stéphan 2016	58	414	57	416	29.5%	1.03 [0.69, 1.52]
Yoo 2016	7	34	13	39	5.8%	0.52 [0.18, 1.50]
Subtotal (95% CI)		**738**		**769**	**62.1%**	**1.07 [0.82, 1.40]**
Total events	131		130			
Heterogeneity: Chi² = 2.40, df = 2 (P = 0.30); I² = 17%						
Test for overall effect: Z = 0.52 (P = 0.60)						
Total (95% CI)		**937**		**977**	**100.0%**	**0.85 [0.68, 1.06]**
Total events	192		225			
Heterogeneity: Chi² = 13.51, df = 5 (P = 0.02); I² = 63%						
Test for overall effect: Z = 1.45 (P = 0.15)						
Test for subgroup differences: Chi² = 10.16, df = 1 (P = 0.001), I² = 90.2%						



Shen and Zhang Critical Care (2017) 21:285

The role of expired Tidal Volume on NIV Failure

Expired TV ml/kg
over the whole duration of NIV

mild hypoxemia
200 < PaO2/FiO2 ≤ 300

Moderate to severe hypoxemia
PaO2/FiO2 ≤ 200 mm Hg

probability of NIV failure
mean TV over 4 Hours

Moderate to severe hypoxemia
PaO2/FiO2 ≤ 200 mm Hg





CONCLUSIONS

A Vte target range of 6–8 mL/kg was impossible to achieve in the majority of patients receiving NIV for de novo AHRF. A higher Vt failure. In the subgroup of patients with a PaO_2/FiO_2 ratio up to 200 mm Hg, a mean Vte of more than 9.5 mL/kg PBW over the first four cumulative hours of NIV accurately predicted NIV failure.

NIV induced lung damage???

Carteaux Get al. Crit Care Med 2016; 44:282–290

Tidal Volume at 1H of NIV



Multivariate Logistic Regression Analyses of Factors Associated With Intubation

In patients treated with conventional O_2 therapy by nonrebreathing mask[a]		
Respiratory rate ≥ 30 breaths/min at H1	2.76 (1.13–6.75)	0.03
In patients treated with high-flow nasal cannula oxygen therapy[a]		
Heart rate at H1 (per beat/min)	1.03 (1.01–1.06)	< 0.01
In patients treated with noninvasive ventilation[ab]		
Tidal volume > 9 mL/kg of predicted body weight at H1	3.14 (1.22–8.06)	0.02
Pao_2/Fio_2 ≤ 200 mm Hg at H1	4.26 (1.62–11.16)	0.003

Frat JP et al Crit Care Med 2018; 46:208–215

High-Flow Nasal Cannula alternating with NIV in acute hypoxemic RF

Sequential application

- ❑ 2-h HFNC
- ❑ 1-h session NIV.

16 h HFNC & 8 h NIV per day



f > 30 br/min at 1 h of the first HFNC session
discrimination between intubated and non-intubated subjects
Sensitivity: 94.1% Specificity: 87.5%



Frat JP et al. Respir Care 2015;60(2):170 –178




VS

Effect of NIV Delivered by Helmet vs Face Mask on the Rate of Endotracheal Intubation in Patients With Acute Respiratory Distress Syndrome: A Randomized Clinical Trial

Patel BK et al. JAMA. 2016 June 14; 315(22): 2435–2441

- ❑ Face mask NIV: 39
- ❑ Helmet NIV: 44

Early termination of the trial

- ➢ PaO2/FiO2<200: 67%
- ➢ High APACHI II score ≈ 25-26
- ➢ 50% immunocompromised



Probability of Survival From Randomization to Day 90



	Noninvasive Ventilation, Median (IQR)		
	Face mask NIV N=39	Helmet NIV N=44	*P* Value
Respiratory Support with NIV			
Duration of NIV, h	26.4 (7.0–60.0)	19.8 (8.4–45.6)	.68
PEEP, cm H_2O	5.1 (5.0–8.0)	8 (5.0–10.0)	.006
Pressure support, cm H_2O	11.2 (10.0–14.5)	8 (5.6–10.0)	<.001
FIO_2,%	60 (50.0–68.6)	50 (40.0–60.0)	.02
SpO_2, %	95.3 (92.3–96.7)	96.2 (94.8–98.4)	.13
Respiratory Rate, breath/min			
Baseline	28.3 (22.1–34.4)[b]	27.7 (21.5–34.6)[b]	
After randomization	29.1 (22.1–37.6)	24.5 (20.4–30.5)	

Patel BK et al. JAMA. 2016 June 14; 315(22): 2435–2441

NIV in acute Hypoxemic RF
de novo RF

Immunocompromised

NONINVASIVE VENTILATION IN IMMUNOSUPPRESSED PATIENTS WITH PULMONARY INFILTRATES, FEVER, AND ACUTE RESPIRATORY FAILURE

Hilbert G et al N Engl J Med 2001;344:481-7

Conclusions: In **selected immunosuppressed patients with pneumonitis and acute respiratory failure**, **early initiation of noninvasive ventilation** is associated with **significant reductions in the rates of endotracheal intubation and serious complications** and an **improved likelihood of survival to hospital discharge**

Noninvasive ventilation for treatment of acute respiratory failure in patients undergoing solid organ transplantation

Antonelli M et al. JAMA 2000;283:235-41

The **use of NIV** was associated with a significant **reduction in the rate of endotracheal intubation (20% vs 70%; P = .002), rate of fatal complications (20% vs 50%; P = .05), length of stay in the intensive care unit by survivors** (mean [SD] days, 5.5 [3] vs 9 [4]; P = .03), and **intensive care unit mortality (20% vs 50%; P = .05**). **Hospital mortality did not differ.**

- ❑ 1,004 patients with solid or hematological malignancies & ARDS
- ❑ 14 ICUs - France & Belgium
- ❑ 1990-2011

Hospital Mortality



NIV initial treatment: 38.6%
NIV failure:71%

Overall Mortality: 64%
Mild ARDS: 59%
Moderate ARDS: 63%
Severe ARDS: 68.5%

Azoulay E et al. Int Care Med (2014) 40:1106–1114

Acute hypoxemic respiratory failure in immunocompromised patients: the Efraim multinational prospective cohort study

Azoulay E et al. Intensive Care Med (2017) 43:1808–1819

- 16 countries (68 centers)
- 1611 immunocompromised with ARF



cause-specific hazard of intubation



Azoulay E et al. Int Care Med 2017;43:1808–19

prevalence of hospital death.



Azoulay E et al. Int Care Med 2017;43:1808–19

Hospital mortality according to the ventilation mode on ICU admission



Azoulay E et al. Int Care Med 2017;43:1808–19

Effect of NIV vs Oxygen Therapy on Mortality Among Immunocompromised Patients With Acute Respiratory Failure

Lemiale V et al. JAMA. 2015;314(16):1711-1719

Incidence of intubation -28 Days



NIV: 38.2%
Oxygen: 44.8%

Probability of Survival at Day 28



Deaths
NIV: 24.1%
Oxygen: 27.3%

PaO2:FIO2 ratio
Oxygen: 130 (86-205)
NIV: 156 (95-248)

- ❑ 374 critically ill immunocompromised patients
- ❑ 28 ICUs in France & Belgium

High-flow nasal oxygen : 141/374 (37.7%)

- ❑ oxygen group: 44.3%
- ❑ NIV group : 31.4%

CONCLUSIONS AND RELEVANCE Among immunocompromised patients admitted to the ICU with hypoxemic acute respiratory failure, early noninvasive ventilation compared with oxygen therapy alone did not reduce 28-day mortality. However, study power was limited.

Effect of non-invasive oxygenation strategies in immunocompromised patients with severe acute respiratory failure: a post-hoc analysis of a randomised trial

Frat JP et al. Lancet Respir Med 2016;4: 646–52

- 82 immunocompromised patients
  - Oxygen : 30
  - High Flow : 26
  - NIV+HF: 26
- 23 ICUs in France & Belgium

Intubation at 28 days

Oxygen	43% (13/30)
High flow	31% (8/26)
NIV+HF	65% (17/26)

Probability of intubation at day 28



NIV

Oxygen

High Flow

PaO2:FIO2 ratio

Oxygen:	155
High Flow:	138
NIV+HF:	149

Probability of survival at day 90



High Flow

Oxygen

NIV

NIV - expired TV at 1h

Survivors: 7.6 mL/kg (SD 3·1) PBW

Died: 11.1 mL/kg (SD 2·6) PBW

PaO2:FIO2 ratio

Oxygen: 155

High Flow: 138

NIV+HF: 149

Factors independently associated with intubation and mortality

	Adjusted OR for intubation	Adjusted OR for intensive care unit mortality	Adjusted HR for 90-day mortality
Age, per year	1·1 (1·0–1·1); p=0·008	1·1 (1·0–1·1); p=0·002	1·0 (1·0–1·1); p=0·003
Randomisation to non-invasive ventilation	4·4 (1·4–14); p=0·013	4·2 (1·3–13·5); p=0·016	3·3 (1·2–5·0); p=0·01

Frat JP et al. Lancet Respir Med 2016;4: 646–52

Mortality

NIV vs initial invasive mechanical ventilation

Study or Subgroup	NIMV Events	NIMV Total	Initial IMV Events	Initial IMV Total	Weight	Risk Ratio M-H, Random, 95% CI
Hilbert 2001	8	15	14	14	5.1%	0.55 [0.34, 0.88]
Azoulay 2001	21	48	34	48	6.9%	0.62 [0.43, 0.89]
Azoulay 2003	3	7	7	8	1.8%	0.49 [0.20, 1.20]
Azoulay 2004	51	93	54	69	10.8%	0.70 [0.56, 0.88]
Depuydt 2004	17	26	34	52	7.4%	1.00 [0.71, 1.41]
Rabbat 2005	8	24	20	23	3.7%	0.38 [0.21, 0.69]
Depuydt 2010	18	24	53	67	9.6%	0.95 [0.73, 1.23]
Gristina 2011	133	274	597	1028	13.6%	0.84 [0.73, 0.95]
Belenguer-Muncharaz 2012	16	35	6	6	6.0%	0.49 [0.33, 0.74]
Molina 2012	85	131	122	169	12.9%	0.90 [0.77, 1.05]
Türkoglu 2013	34	46	17	21	9.4%	0.91 [0.70, 1.20]
Grgic Medic 2014	17	28	77	88	8.3%	0.69 [0.51, 0.94]
Azevedo 2014	8	16	19	20	4.6%	0.53 [0.32, 0.87]
Total (95% CI)		**767**		**1613**	**100.0%**	**0.74 [0.65, 0.84]**
Total events	419		1054			

Heterogeneity: Tau² = 0.03; Chi² = 28.41, df = 12 (P = 0.005); I² = 58%

Test for overall effect: Z = 4.66 (P < 0.00001)



Favours NIV **Favours IMV**

NIV failure: 61% (40-78% in various studies)

Amado-Rodríguez L et al. Crit Care Med 2016;44:1406–1413

MORTALITY

NIV Failure vs initial invasive mechanical ventilation

Study or Subgroup	NIMV failure Events	NIMV failure Total	Initial IMV Events	Initial IMV Total	Weight	Risk Ratio M-H, Random, 95% CI
Hilbert 2001	8	8	14	14	12.6%	1.00 [0.83, 1.20]
Azoulay 2003	3	4	7	8	2.2%	0.86 [0.46, 1.60]
Depuydt 2004	16	18	34	52	8.8%	1.36 [1.05, 1.76]
Azoulay 2004	46	59	54	69	12.6%	1.00 [0.83, 1.20]
Rabbat 2005	8	16	20	23	3.1%	0.57 [0.34, 0.96]
Gristina 2011	83	127	597	1028	15.7%	1.13 [0.98, 1.29]
Molina 2012	63	79	122	169	15.1%	1.10 [0.96, 1.28]
Belenguer-Muncharaz 2012	10	14	6	6	4.9%	0.75 [0.51, 1.11]
Türkoglu 2013	32	36	17	21	9.7%	1.10 [0.87, 1.39]
Grgic Medic 2014	15	17	77	88	12.2%	1.01 [0.83, 1.22]
Azevedo 2014	6	10	19	20	3.1%	0.63 [0.38, 1.06]
Total (95% CI)		**388**		**1498**	**100.0%**	**1.02 [0.93, 1.13]**
Total events	290		967			

Heterogeneity: $Tau^2 = 0.01$; $Chi^2 = 18.41$, df = 10 (P = 0.05); $I^2 = 46\%$

Test for overall effect: Z = 0.44 (P = 0.66)



Favours NIV **Favours IMV**

NIV failure: 61% (40-78% in various studies)

Amado-Rodríguez L et al. Crit Care Med 2016;44:1406–1413

Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure

Eur Respir J 2017; 50 (2): 1602426

Should NIV be used for ARF in immunocompromised patients?

Recommendation

- **We suggest early NIV for immunocompromised patients with ARF.**
  (Conditional recommendation, moderate certainty of evidence.)



Emergency Department

- 45 YO, smoker
- Fever, ARDS on x-ray
- Hypoxemia, PaO2/FiO2:150mmHg
- RR:28/min
- HR:125/min
- pH:7.48, PCO2: 30mmHg, PO2:90mmHg, FiO2:60%
- Without shock

- **After 6 hours**
- Hypoxemia, PaO2:75mmHg FiO2:100mmHg
- RR:33/min
- HR:130/min
- pH:7.42, PCO2: 38mmHg
- Without shock

ICU-NIV initiation

prediction of NIV failure in de novo ARF

The HACOR score 0-25

Variable	Category	Assigned points
Heart rate, beats/min	≤120	0
	≥121	1
pH	≥7.35	0
	7.30–7.34	2
	7.25–7.29	3
	<7.25	4
Glasgow Coma Scale	15	0
	13–14	2
	11–12	5
	≤10	10
PaO_2/FiO_2 ratio, mm Hg	≥201	0
	176–200	2
	151–175	3
	126–150	4
	101–125	5
	≤100	6
Respiratory rate, breaths/min	≤30	0
	31–35	1
	36–40	2
	41–45	3
	≥46	4

cut-off value: 5 after 1 hour of NIV

SE (%)	SP (%)	PPV (%)	NPV (%)
73.9	91.4	87.1	81.6

HACOR score of ≤5,

- NIV failure rate:18.4% &
- Hospital mortality: 21.6%.

HACOR score of >5,

- NIV failure rate:87.1%
- Hospital mortality: 65.2%.

Duan J et al. Int Care Med (2017) 43:192–199

cut-off value of 5 after 1 hour of NIV



HACOR Score at 1h of NIV





Duan J et al. Int Care Med (2017) 43:192–199



- **After 6 hours**
- Hypoxemia, PaO2:75mmHg FiO2:100mmHg
- RR:33/min
- HR:130/min
- pH:7.42, PCO2: 38mmHg
- Without shock

INTUBATION & MECHANICHAL VENTILATION

ICU-NIV
At 1hour
- RR:28/min
- HR:128
- **PaO2/FiO2:125**
- pH: 7,42

- **Tve:9ml/kg**
- **HACOR:6**

ICU-NIV
At 6hour
- RR:30/min
- HR:126
- **PaO2/FiO2:105**
- pH: 7,38

- **Tve:9.5ml/kg**
- **HACOR:6**

ICU-NIV
At 12hour
- RR:32/min
- HR:128
- **PaO2/FiO2:90**
- pH: 7,34

- **Tve:10.5ml/kg**
- **HACOR:10**

- **WHO:** de novo ARF
  Immunocompromised ARF

  EARLY
  - PaO2/FiO2 >150mmHg ή 200>mmHg

- **HOW:**
  - NIV alternating with HFNC ???
  - Helmet NIV vs face mask???
    - High flow rates, short inspiratory rise time, cycling to 50% of peak inspiratory flow)

- **HOW LONG**
  - **STOP**
  - HACOR SCORE>5 at 1h of NIV
  - TV>9 ml/kg PBW at 1h of NIV
  - PaO2/FiO2 <200 at 1h of NIV